Supplementary materials

1. Full search strategy
2. Excluded studies table with reasons
3. Signalling questions for risk of bias assessment

Supplement 1. Full search strategy for all databases run on 08/04/2020 and updated on 14/05/2020

PubMed search


AND


AND


OR


AND

(Asymptomatic[ti] OR Presymptomatic[ti] OR “Pre-Symptomatic”[ti])

AND (“2019/01/01”[PDat] : “2020/12/31”[PDat])

Embase search


AND

(Assemblerotic disease'/exp OR Asymptomatic:ti,ab OR Presymptomatic:ti,ab OR Pre-Symptomatic:ti,ab OR "No symptoms":ti,ab OR "No symptom":ti,ab OR "Silent transmission":ti,ab OR "Silent carrier":ti,ab OR "Silent carriers":ti,ab)

AND

('letter'/exp OR 'epidemiology'/exp OR 'case control study'/exp OR 'cohort analysis'/exp OR "Case control”:ti,ab OR Longitudinal:ti,ab OR Prospective:ti,ab OR Retrospective:ti,ab OR "Cross sectional”:ti,ab OR 'cross-sectional study'/exp OR Investigated:ti,ab OR Analysis:ti,ab OR Data:ti,ab OR Cases:ti,ab OR Ratio:ti,ab)

OR


AND

(Assemblerotic:ti OR Presymptomatic:ti OR Pre-Symptomatic:ti)

AND [2019-2020]/py

Cochrane Covid-19 study register

"Asymptomatic Diseases" OR "Viral Load" OR Asymptomatic OR Presymptomatic OR Pre-Symptomatic OR "No symptoms" OR "No symptom" OR "Silent transmission" OR "Silent carrier" OR "Silent carriers"

MedRxiv (pre-print servers) search via Europe PMC


AND

(Assemblerotic OR Presymptomatic OR "No symptoms" OR "No symptom” OR “Silent transmission” OR “Silent carrier” OR “Silent carriers”)
# Supplement 2. Excluded studies after full text assessment with reasons

<table>
<thead>
<tr>
<th>#</th>
<th>Reference</th>
<th>Reason for exclusion</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Tian S, et al., Characteristics of COVID-19 infection in Beijing, J Infect 80, 401-406</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>2</td>
<td>Chen, P., et al., Epidemiological and clinical characteristics of 136 cases of COVID-19 in main district of Chongqing, J Formos Med Assoc, 2020</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>3</td>
<td>Feng, T., et al., A study on the clinical characteristics and management of patients with mild cases of COVID-19 in shelter hospitals from China, 2020, Research Square</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>5</td>
<td>Mandić-Rajčević, S., et al., Contact tracing and isolation of asymptomatic spreaders to successfully control the COVID-19 epidemic among healthcare workers in Milan (Italy), 2020, medRxiv</td>
<td>Unclear sampling frame</td>
<td>Italy</td>
</tr>
<tr>
<td>6</td>
<td>Du W, Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China, Infection, 2020</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>7</td>
<td>Ben-Ami, R., et al., Large-scale implementation of pooled RNA-extraction and RT-PCR for SARS-CoV-2 detection, 2020, medRxiv</td>
<td>Unclear sampling frame</td>
<td>USA</td>
</tr>
<tr>
<td>8</td>
<td>An, P., et al., Asymptomatic Patients with Novel Coronavirus Disease (COVID-19), Balkan Med J, 2020</td>
<td>Unclear sampling frame</td>
<td>Japan</td>
</tr>
<tr>
<td>9</td>
<td>Chau, N.V.V., et al., The natural history and transmission potential of asymptomatic SARS-CoV-2 infection, 2020, medRxiv</td>
<td>Unclear sampling frame</td>
<td>Vietnam</td>
</tr>
<tr>
<td>10</td>
<td>Breslin, N., et al., Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals, American Journal of Obstetrics and Gynecology MFM, 2020</td>
<td>Unclear sampling frame</td>
<td>USA</td>
</tr>
<tr>
<td>12</td>
<td>Wong J, et al., High proportion of asymptomatic and presymptomatic COVID-19 infections in travelers and returning residents to Brunei, Journal of travel medicine, 2020</td>
<td>Unclear sampling frame</td>
<td>Brunei</td>
</tr>
<tr>
<td>13</td>
<td>Kim Se, et al., Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients, International journal of infectious diseases, 2020</td>
<td>Unclear sampling frame</td>
<td>Korea</td>
</tr>
<tr>
<td>14</td>
<td>Liao J, et al., Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>15</td>
<td>Corman, V., et al., SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission, 2020, medRxiv</td>
<td>Unclear sampling frame</td>
<td>Germany</td>
</tr>
<tr>
<td>16</td>
<td>Day, M., Covid-19: four fifths of cases are asymptomatic, China figures indicate. Bmj, 2020. 369: p. m1375</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>19</td>
<td>Qiu, C., et al., Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China, 2020, medRxiv</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>20</td>
<td>Tao, Y., et al., High incidence of asymptomatic SARS-CoV-2 infection, Chongqing, China, 2020, medRxiv</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>22</td>
<td>Zhang, Z., et al., Clinical characteristics of COVID-19 in children compared with adults in Shandong, China. 2020, Research Square</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
<tr>
<td>26</td>
<td>Zhou, X., et al., Follow-up of the asymptomatic patients with SARS-CoV-2 infection. Clin Microbiol Infect, 2020</td>
<td>Unclear sampling frame</td>
<td>China</td>
</tr>
</tbody>
</table>
86 Song, H., et al., A considerable proportion of individuals with asymptomatic SARS-CoV-2 infection in Tibetan population. 2020, medRxiv.


89 Li Q, et al., Early transmission dynamics in Wuhan, China, of Novel Coronavirus - Infected pneumonia


94 Philip P et al., Testing of NHS staff and household members


96 WHO Coronavirus Disease Situation Report 84, April 13, 2020

97 Rothe C., et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany


110 Serra M, Case studies of blood donors


Supplement 3. Risk of bias assessment signalling questions

1. Was the sampling frame a true or close representation of the target population (all at risk of SARS-CoV-2 infection)?
   1a. What method of sampling was used? Complete sampling (census), Random selection, Other?
   1b. Is there likely to be bias from selection of a study population that doesn’t match the target population (all at risk of the infection)?

2. Was there incomplete ascertainment of infection status in the study population?
   2a. Was a reference standard applied to everyone (or a random sample) of the study population? Is the probability of having a reference standard applied different for people without symptoms/with mild symptoms/with severe symptoms?
   2b. Is there likely to be bias from incomplete ascertainment of infection status in the study population?

3. Were acceptable methods used to identify individuals in the study population who had SARS-CoV-2 infection (denominator for research question)?
   3a. What reference standards were used to determine SARS-CoV-2 infection status, and what is the estimated diagnostic accuracy for these? Did the choice of reference standard differ depending on whether or not symptoms were present, and the severity of symptoms?
   3b. Is there likely to be bias from differential application of reference standards to define infection status

4. Was an acceptable case definition used in the study (numerator for the research question)?
   4a. What was the definition of asymptomatic infection? Was there distinction between asymptomatic and minimally symptomatic?
   4b. Is there likely to be bias from the definition of asymptomatic infection?

5. Was the length of follow-up to define case definition (asymptomatic infection) appropriate?
   5a. Was the follow-up of people without symptoms sufficient to allow for the incubation period, to allow classification as asymptomatic vs pre-symptomatic?
   5b. Is there likely to be bias from insufficient follow-up?